The major receptors utilized to develop hormonal therapies against breast cancer, including human epidermal growth factor 2 receptors (HER2), estrogen receptors (ER), and progesterone receptors (PR), are lost in TNBC, making it difficult to treat with conventional therapies2. Here, ESR1 is linked to breast carcinoma.